CD8A and breast cancer: It also increased mortality rate, although there was no difference (Figure 3(g) and Figure S3m, S3n), indicating that CD8+ and not CD4+ T cells were required for BC-mediated protection from IAV PR8 at the early phase of activation of adaptive immunity.